Accueil   Diary - News   All news Osivax Announces Publication of Phase 1 Data on its Broad-Spectrum Influenza Vaccine Candidate OVX836 in the Journal of Infectious Diseases

Osivax Announces Publication of Phase 1 Data on its Broad-Spectrum Influenza Vaccine Candidate OVX836 in the Journal of Infectious Diseases

 

 

Encouraging safety and cellular immune response data as well as a promising reactogenicity profile warrant further evaluation of OVX836 in Phase 2a study

 

Lyon, France – December 2nd, 2021 – Osivax, a biopharmaceutical company focused on the development of universal vaccines against highly-mutating viruses, including influenza and coronaviruses, announced today the publication of results of its Phase 1 clinical trial with OVX836 titled “Phase 1 Randomized, PlaceboControlled, Dose Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results” in the Journal of Infectious Diseases. OVX836 is Osivax’ lead universal influenza vaccine candidate developed using the company’s proprietary oligoDOM® technology platform.

 

 

Read the press release